Sunosi Demonstrating Improved Cognitive Function in Sleep Apnea Patients with EDS
Axsome Therapeutic Inc will present data on Sunosi (solriamfetol), including results from the SHARP study, at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30 to June 3 in Miami. According to the company, Sunosi is demonstrating improvement in cognitive function in patients with excessive daytime sleepiness associated with obstructive…